Bernadette Connaughton Sells 1,626 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Wednesday, July 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75.
• On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25.

Halozyme Therapeutics Stock Performance

HALO stock opened at $101.79 on Thursday. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $104.78. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a market cap of $11.55 billion, a P/E ratio of 30.39, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. The business’s fifty day moving average is $78.53 and its 200-day moving average is $72.14.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on HALO shares. Morgan Stanley lowered their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. TD Cowen raised their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Finally, Wells Fargo & Company upped their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.20.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares in the last quarter. MidFirst Bank bought a new position in Halozyme Therapeutics during the second quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics during the second quarter worth about $28,000. Finally, Quantbot Technologies LP acquired a new stake in Halozyme Therapeutics in the 2nd quarter worth about $30,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.